Numerous treatment strategies are available for atrial and ventricular arrhythmias, though the risk of side effects and incomplete effectiveness limit their clinical use. Cardiomyocyte culture models provide a high-throughput platform for screening novel compounds for anti-arrhythmic properties, but characterisation of their basic electrophysiological properties is lacking.
Numerous treatment strategies are available for atrial and ventricular arrhythmias, though the risk of side effects and incomplete effectiveness limit their clinical use. Cardiomyocyte culture models provide a high-throughput platform for screening novel compounds for anti-arrhythmic properties, but characterisation of their basic electrophysiological properties is lacking.
This study aimed to directly compare the electrophysiological properties of three commonly used cardiac cultures -neonatal rat ventricular myocytes (NRVM), immortalised atrial HL-1 cells and human iPSC derived cardiomyocytes (hiPSC-CM). Cells were cultured on multi-electrode arrays (MEA) for 48-120 hrs. Extracellular field potentials (FP) were recorded and conduction velocity (CV) mapped in the presence or absence of 1 M isoproterenol to assess ␤-adrenergic responsiveness.
Spontaneous beating rate was significantly faster in hiPSC-CMs (NRVM vs HL-1 vs hiPSC-CM, bpm: 81.5 ± 6.9 vs 49.7 ± 5.6 vs 162.5 ± 38.0; p < 0.05), and FP morphology differed between all cell types. FP amplitude was greatest in NRVMs (mV: 2.95 ± 0.58 vs 0.26 ± 0.02 vs 0.40 ± 0.09; p < 0.05) and FP duration significantly shorter in HL-1 cells (ms: 40.2 ± 1.4 vs 184.0 ± 10.5 vs 146.9 ± 23.2; p < 0.0001). HL-1 cells also exhibited slower conduction velocities (NRVM vs HL-1, cm/s: 24.25 ± 1.91 vs 0.83 ± 0.03; p < 0.0001) and did not respond to isoproterenol, in contrast to NRVM and hiPSC-CM.
This is the first study to quantify the inherent disparities in cardiac cell culture electrophysiology and the necessity to factor in these cellular properties when selecting culture models. These findings are an important step towards the standardisation of cultured cardiomyocyte MEA that will be essential to its application as a high-throughput platform for anti-arrhythmic drug development. Mitochondria produce more than 90% of the energy required by our bodies and thereby have a fundamental role in cell and energy metabolism. Mitochondria are composed of proteins encoded by both the nuclear and mitochondrial genomes and the coordinated expression of both genomes is essential for energy production. Impaired energy production leads to mitochondrial dysfunction that causes or contributes significantly to a variety of diseases including metabolic disorders and cardiovascular diseases. How uncoordinated gene expression causes mitochondrial dysfunction and compromised energy production in heart and metabolic diseases is poorly understood, making it difficult to develop effective treatments. We have created a new model of cardiovascular disease caused by loss of an essential nuclear encoded RNAbinding protein, involved in the regulation of mitochondrial protein synthesis. Loss of this RNA-binding protein is embryonic lethal, so to characterise its molecular role we developed and investigated a homozygous heart-and skeletal-musclespecific knockout (KO) mouse model. At 25 weeks KO mice weighed approximately 25% less than wild-type (wt) counterparts, and exhibited a significantly increased heart weight to body weight ratio (0.64% ± 0.03, n = 4) versus wt mice (0.44% ± 0.02, n = 5, p < 0.05). Echocardiography revealed that KO mice developed dilated cardiomyopathy by 25 weeks, with a significant decrease in fractional shortening, posterior wall and intraventricular septum thickness versus wt mice (n = 4, p < 0.05). Experiments to characterise its molecular function indicate that this protein is essential for coordinated expression of mitochondrial genes and proteins, assembly and function of the electron transport chain and ultimately heart function. http://dx.doi.org/10.1016/j.hlc.2019.06.036
